2023年12月23日～2024年1月5日の間に収集した論文情報を追加しました。
1. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
FAERSにおけるエンドセリン受容体拮抗剤と肝障害の関連性を検証
対象DB：FAERS
2. Effect of acid suppressant medications on the laxative action of magnesium preparations in patients with opioid-induced constipation: A pharmacovigilance analysis of the FDA Adverse Event Reporting System.
マグネシウム製剤と酸抑制剤の併用と便秘の関連についての研究
対象DB：FAERS
3. Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS.
FAERSの薬物名を有効成分でシステマティックにマッピングするDiAna辞書を導入
対象DB：FAERS
4. Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety.
ピトリサントの安全性をFAERSから分析
対象DB：FAERS
5. Exploring the incidence and etiopathogenesis of pathological yawning as adverse side effect of psychotropic drugs.
「病的なあくび」の特性と薬物との関連性を3つのデータベースから調査
対象DB：CVAR,FAERS
6. Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials.
ベバシズマブの安全性再評価：RWDとRCTとの比較
対象DB：FAERS
7. Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes.
FAERSから性差のある薬剤有害事象（SBAEs）と関連する薬物の遺伝子発現を解析
対象DB：FAERS
8. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
CAR-T療法における神経系毒性に関するFAERSデータ解析
対象DB：FAERS
9. Vaccination and clozapine use: a systematic review and an analysis of the VAERS database.
クロザピンとワクチン接種の相互作用に関する現在のエビデンスを総合的に調査
対象DB：FAERS,VAERS
10. Descriptive analysis on disproportionate medication errors and associated patient characteristics in the Food and Drug Administration's Adverse Event Reporting System.
FAERSを用いた医薬品誤用の特性を分析
対象DB：FAERS
11. Evaluation of four machine learning models for signal detection.
FAERSを用いたロジスティック回帰、グラディエントブースティングツリー、ランダムフォレスト、サポートベクターマシンの性能比較
対象DB：FAERS
12. Olfactory-Related Adverse Events: An Analysis of the Food and Drug Administration Adverse Events Reporting System.
FAERSにおける嗅覚障害に関する調査
対象DB：FAERS
13. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.
抗GD2モノクローナル抗体の毒性プロファイルをFAERSから解析
対象DB：FAERS
14. Concomitant Use of Multiple Nephrotoxins including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases.
バンコマイシン関連腎毒性と腎毒性薬の併用の関係を調査
対象DB：FAERS
15. A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system.
FAERSにおけるメポリズマブに関連する有害事象の調査
対象DB：FAERS
16. The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database.
男性不妊症と関連する薬物をFAERSで特定
対象DB：FAERS
17. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database.
FAERSでのダラツムマブの副作用分析
対象DB：FAERS
18. Long-term efficacies of selective vasodilators in pulmonary arterial hypertension: a comprehensive comparison using a spontaneous reporting database.
肺動脈性肺高血圧症における薬剤の長期生存率への影響を評価
対象DB：JADER
19. COVID-19 vaccine-associated myocarditis: Analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature.
COVID-19ワクチン接種後の心筋炎報告ケースをEudraVigilanceと文献から分析
対象DB：EudraVigilance
20. Comparison of reporting rates of arthritis and arthralgia following AstraZeneca, Pfizer-BioNTech, Moderna, and Janssen vaccine administration against SARS-CoV-2 in 2021: analysis of European pharmacovigilance large-scale data.
欧州でのCOVID-19ワクチン接種後の関節痛と関節炎報告率を比較
対象DB：EudraVigilance
21. [Monitoring of adverse drug reactions during seasonal malaria chemoprevention campaigns in children aged 3-59 months in Burkina Faso].
ブルキナファソでの季節性マラリア予防の副作用報告に関する研究
対象DB：VigiBase
22. Analysis of clinical factors associated with Kampo formula-induced pseudoaldosteronism based on self-reported information from the Japanese Adverse Drug Event Report database.
漢方薬の擬アルドステロン症の実データからのリスク要因の抽出
対象DB：JADER
23. Short-term outcomes of laparoscopic and robotic distal gastrectomy for gastric cancer: Real-world evidence from a large-scale inpatient database in Japan.
2018年に保険適用された日本の実データで、胃癌のロボット補助と腹腔鏡下の胃切除手術の短期成績を比較
対象DB：DPC
24. Association between hospital spending and in-hospital mortality of patients with sepsis based on a Japanese nationwide medical claims database study.
日本の敗血症患者における病院の医療費支出と死亡率の相関
対象DB：DPC
25. Temporal trends in antipsychotic prescriptions for pediatric patients using an administrative hospital database in Japan: a retrospective study.
日本の小児精神分裂病患者に対する抗精神病薬処方の傾向
対象DB：DPC
26. Demographic profiles and risk factors for mortality in acute meningitis: A nationwide population-based observational study.
各種細菌性、ウイルス性、真菌性、結核性、癌性髄膜炎の死亡率とリスクを分析
対象DB：DPC
27. Timing of Worsening Renal Function in Patients Hospitalized for Heart Failure Exacerbation Who Were Being Treated With Intravenous Diuretic Therapy.
日本の心不全患者と入院前の腎機能の関連
対象DB：DPC
28. Estimated number of spine surgeries and related deaths in Japan from 2014 to 2020.
2020年日本における脊椎手術の推定件数は約20万件、関連死亡数は年間200?800件と推測
対象DB：NDB
29. Study of Factors to Increase the Usage Rate of Generic Drugs in Platelet Aggregation Inhibitors.
ジェネリック薬の使用率を高め、高所得者の利用促進で費用低減を目指す
対象DB：NDB
30. Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.
日本の慢性リンパ性白血病患者、小リンパ球性リンパ腫患者、共有結合ブルトン型チロシンキナーゼ阻害薬治療後の治療パターンを調査
対象DB：MDV
31. Real-World Amount of Clotting Factor Concentrates Dispensed and Annual Medical Expenditures for Japanese Patients with Hemophilia B.
日本の血友病B治療における医療費とEHL凝固因子の処方量の研究
対象DB：MDV
32. NSAID prescribing and adverse outcomes in common infections: a population-based cohort study.
呼吸器感染または尿路感染の患者におけるNSAIDs処方と入院・死亡率の関連
対象DB：CPRD
33. Healthcare resource utilisation and costs of hospitalisation and primary care among adults with COVID-19 in England: a population-based cohort study.
英国での成人における急性COVID-19に関連する医療費とリソース利用の調査
対象DB：CPRD
34. Fracture patterns and associated risk factors in pediatric and early adulthood type 1 diabetes: Findings from a nationwide retrospective cohort study.
小児および若年成人の1型糖尿病患者では全体的な骨折リスクは増加しない傾向
対象DB：CPRD
35. Risk of Falls and Fractures in Individuals With Cataract, Age-Related Macular Degeneration, or Glaucoma.
白内障、加齢黄斑変性、緑内障の患者の転倒と骨折リスクの検討
対象DB：CPRD
36. Temporal trends and patterns in initial opioid prescriptions after hospital discharge following colectomy in England over 10 years.
手術後の初回オピオイド処方の変化を調査
対象DB：CPRD
37. The incidence and prevalence of Juvenile Idiopathic Arthritis differs between ethnic groups in England.
国内初の若年性特発性関節炎の発症率・有病率推定
対象DB：CPRD